Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion

AAPS PharmSciTech

Volumn 4, Issue 1, 2003, Pages

  Gondaliya, Deepak ^a,b   Pundarikakshudu, Kilambi ^a  

^a GANPAT UNIVERSITY   (India)

^b Torrent Pharmaceuticals Ltd   (India)

Author keywords

Bupropion free base; Epidermal flux; In vitro release study; Plasticizers; Release modifiers; Unilaminate transdermal adhesive matrix

Indexed keywords

ACETONE; ADHESIVE AGENT; AMFEBUTAMONE; CITRIC ACID TRIETHYL ESTER; EUDRAGIT; MACROGOL; MYRISTIC ACID; PHTHALIC ACID DIBUTYL ESTER; PLASTICIZER; POLYMER; SUCCINIC ACID; ANTIDEPRESSANT AGENT; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYMETHACRYLIC ACID DERIVATIVE;

ARTICLE; CADAVER; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSS LINKING; DRUG ABSORPTION; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; PROCESS DESIGN; TRANSDERMAL PATCH; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; EPIDERMIS; KINETICS; METABOLISM;

ADHESIVES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; EPIDERMIS; HUMANS; KINETICS; PLASTICIZERS; POLYMETHACRYLIC ACIDS;

EID: 0141688425     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt040103     Document Type: Article

References (16)

1. Laizure SC. Pharmacokinetics of bupropion and its major basic metabolites in normal subjects after a single dose. Clin Pharmacol Ther. 1985;38:586-589.
2. Sweet RA. Pharmacokinetics of single and multiple dose bupropion in elderly patients with depression. J Clin Pharmacol. 1995;35:875-884.
3. Goldberg-Cettina M, Liu P, Nightingle J, Kurihora-Bergstrom T. Enhanced transdermal delivery of estradiol in vitro using binary vehicles of isopropyl myristate and short chain alkanols. In J Pharm. 1995;114:237-245.
4. Chien YW. Rate-control drug delivery system: controlled release versus sustained release. Med Prog Tech. 1989;15:21-46.
5. Yu JW, Chien TY, Chien YW. Transdermal dual controlled delivery of testosterone and estradiol: impact of system design. Drug Dev Ind Pharm. 1991;17:1883-1904.
6. Chien YW. Concept and system design for the rate controlled drug delivery. In: Chien YW, ed. Novel Drug Delivery Systems. 2nd ed. New York, NY: Marcel Dekker, Inc; 1992:1-42.
7. Loth H. Vehicular influence on transdermal drug penetration. Int J Pharm. 1991;68:1-10.
8. Stantus GC, Baker RW. Transdermal enhancer patent literature. J Control Release. 1993;25:1-20.
9. Barrickman LL. Bupropion versus methylphenidate in the treatment of attention-deficit hypersensitivity disorder. J Am Acad Adoles Psychiatry. 1995;34(5):649-657.
10. Lehman K. Chemistry and application properties of polymethacrylate coating systems. In: Mcginigy JW, ed. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms. New York, NY: Marcel Dekker, Inc; 1989:101-176.
11. Peppas KA, Meadows DL. Macromolecular structure and solute diffusion in membranes: an overview of recent theories. J Membrane Sci. 1982;16:361-377.
12. Raffiee-Tehrani M, Safaii-Nikui N, Toliat T, Petereit H, Beckert T. Acrylic resins as rate controlling membranes in delivery unilaminate device of estradiol. 25th Int Symp Controlled Release Bioact Mater. 1998:28-29.
13. Raffiee-Tehrani M, Safaii-Nikui N, Toliat T, Petereit H, Beckert T. Effect of plasticizers and enhancers on release behavior of estradiol from unilaminate TDD patch. 26th Int Symp Controlled Release Bioact Mater. 1999:455-456.
14. Poulsen BJ, Young E, Coquilla V, Katz M. Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate esters. J Pharm Sci. 1968;57:928-933.
15. Cooper ER. Increased skin permeability for lipophilic molecules. J Pharm Sci. 1984;73:1153-1156.
16. Aungst BJ, Blake JA, Rogers NJ, Hussain MA. Transdermal oxymorphine formulation development and methods for evaluating flux and lag times for two skin enhancing vehicles. J Pharm Sci. 1990;79:1072-1076.